We have found that pricing competition continues to intensify as new products enter the market, with Australian doctors now having a choice of over 50 products to prescribe from.

Patient dosages have increased as the market matures and more patients find their ‘optimal’ dose requirements, and this has led to a slight increase in average monthly costs for patients. We expect around 15,000 – 20,000 new patients to enter the market this year, with monthly product revenues to approach A$3.6M by the end of 2019.

We expect around 15,000 – 20,000 new patients to enter the market this year, with monthly product revenues to approach A$3.6M by the end of 2019.